www.ijbcp.com International Journal of Basic & Clinical Pharmacology | December 2018 | Vol 7 | Issue 12 Page 1 IJBCP International Journal of Basic & Clinical Pharmacology Print ISSN: 2319-2003 | Online ISSN: 2279-0780 New Drug Update Ertugliflozin: a novel anti-diabetic drug Vikrant Sharma, Sonika Sharma, Sanjay Jaiswal*, Ravi R. Ghanghas, Durgaprasad Boddepalli, Ashok Kumar Sharma INTRODUCTION Diabetes mellitus is a disorder of global proportion. Despite various treatment modalities presently being available, yet the desired glycaemic control and patient outcomes have not been achieved completely. Hence, there is an unmet need to develop new drugs which would benefit most patients. Sodium glucose co-transporter type 2 inhibitors (SGLT2 inhibitors) are one such promising group of emerging drugs in diabetes treatment. Manufacturing and processing of SGLT2 inhibitor drugs have been a challenge for the pharmaceutical industry. Ertugliflozin is the latest in the series to be approved by the US Food and Drug Administration for type 2 diabetes in December 2017. In addition to euglycaemia, the drug benefits patients in control of systolic blood pressure and body weight, which is of paramount importance. The European Medicines Agency has also opined that benefits outweigh the risks when Ertugliflozin is prescribed to T2DM patients. 1 CHEMICAL STRUCTURE OF ERTUGLIFLOZIN Ertugliflozin is chemically (C22H25ClO7): (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl) phenyl]-1-hydroxymethyl6,8-dioxabicyclo[3.2.1] octane- 2,3,4-triol. 2 The molecular structure of Ertugliflozin is depicted in Figure 1. 2 ABSTRACT Diabetes Mellitus is a disorder of global proportion. Despite various treatment modalities presently being available, yet the desired glycaemic control and patient outcomes have not been achieved completely. Sodium glucose co-transporter type 2 inhibitors (SGLT2 inhibitors) are one such promising group of emerging drugs in diabetes treatment. Ertugliflozin prevents the reabsorption of glucose by inhibiting sodium-glucose cotransporter-2 (SGLT2) at proximal convoluted tubules. Ertugliflozin is available as 5mg and 15mg tablets. Ertugliflozin has been related to genital mycotic infections and urinary tract infections. Benefits of Ertugliflozin include better control on blood glucose, body weight and blood pressure. Keywords: Diabetes mellitus, Ertugliflozin, SGLT2 inhibitor DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20184607 Department of Pharmacology, Armed Forces Medical College (AFMC). Pune, Maharashtra, India Received: 17 October 2018 Accepted: 22 October 2018 *Correspondence to: Dr. Sanjay Jaiswal, Email: sanjayjais@gmail.com Copyright: © the author(s), publisher and licensee Medip Academy. This is an open- access article distributed under the terms of the Creative Commons Attribution Non- Commercial License, which permits unrestricted non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.